Sparsentan (Filspari®). HTA ID: 24020

Assessment Status Rapid Review complete
HTA ID 24020
Drug Sparsentan
Brand Filspari®
Indication For the treatment of adults with primary immunoglobulin A (IgA) nephropathy with a urine protein excretion >1.0 g/day (or urine protein-to-creatine ratio ≥0.75 g/g).
Assessment Process
Rapid review commissioned 30/05/2024
Rapid review completed 26/06/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of sparsentan compared with the current standard of care.